Canaccord reiterates Hims & Hers stock rating on peptide launch

Canaccord Genuity reiterated a Buy rating and $40 price target for Hims & Hers Health (HIMS) after its launch of Peptides+ treatment line. The company reported Q3 revenue of $890M, up 49% YoY, but saw a subscriber decline. Analysts have mixed views on its outlook, with some lowering price targets due to subscriber losses and others optimistic about future growth.

Original reporting
Published Nov 18, 2026, 5:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 5:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$HIMS
Bullish
high confidence
Mentioned
$HIMS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HIMSBullishMed
01

Why it matters

Analyst upgrade with a $40 target may attract new buying, but subscriber churn and regulatory approvals for future peptides pose risks.

02

Market read

The combination of a product launch and an analyst rating upgrade creates a short‑term catalyst for HIMS, with potential upside if the peptide line gains traction.

03

What to watch

Potential supply‑chain constraints for BPC‑157 and TB‑500 and the sequential subscriber decline could temper growth.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

Hims & Hers Health (NYSE:HIMS) reported Q3 results and announced a new Peptides+ line, prompting analyst rating reaffirmation and a higher price target.

Company-level read

Ticker impact

$HIMSBullishHigh confidence
Context

Canaccord Genuity reiterated a Buy rating and raised the price target to $40 following Hims & Hers Health's launch of its new Peptides+ treatment line.

Expected impact

likely upward pressure as investors price in the higher target and growth potential of the peptide line

Evidence & confidence

Analyst upgrade with a concrete $40 target and a novel product launch provide a clear catalyst for short‑term upside.

Market effects

The launch highlights growing interest in specialty injectable therapies, potentially benefiting other biotech firms in the peptide/anti‑aging space.

U.S. biotech sector may see modest uplift as investors reassess pipeline valuations.

Limited to U.S. listed biotech; no immediate global macro impact.

Counterpoint

The peptide market is still nascent and regulatory risk remains; the $40 target may be overly optimistic given uncertain reimbursement.

Key entities

  • Canaccord Genuity

    Equity research firm that reiterated a Buy rating and set a $40 price target.

  • Hims & Hers Health

    Provider of telehealth and wellness products launching the Peptides+ line.

Related articles

$HIMSHighAI 8/10

Should Hims & Hers Stock's Drop After Earnings Worry You?

Hims & Hers Health (HIMS) stock dropped 16.6% after reporting Q3 2026 earnings. Revenue of $890M missed estimates by 2.2%, and EPS was -$0.10 vs. expected $0.06 profit. Subscribers fell by 100,000 to 2.8M. Management cut full-year EBITDA and revenue forecasts, citing marketing adjustments and delayed revenue recognition.

$HIMSMed

Wisconsin joins federal lawsuit against Hims & Hers telehealth provider

Wisconsin joined a federal lawsuit against Hims & Hers Health, alleging the telehealth provider shared customer health data with Meta and Snapchat, and engaged in deceptive subscription practices. The state seeks an injunction and restitution. Hims denies wrongdoing, stating it provides clear information to customers. The FTC and six other states are also involved.

$HIMSHighAI 8/10

Hims & Hers Revenue Climbs 49% as Gross Margin Falls to 57%

Hims & Hers reported Q3 2026 revenue of $890.4M, up 49% YoY, but gross margin fell to 57% from 74%. Net loss was $33M vs. $15.8M net income a year ago. Adjusted EBITDA rose to $82.4M. The company forecasts Q4 revenue of $875M-$895M and full-year revenue of $3.13B-$3.15B, but lowered adjusted EBITDA guidance to $257M-$277M.